<p>US and European regulators could approve Pfizer and BioNTech's experimental Covid-19 vaccine as early as mid-December, the German firm's chief executive said on Wednesday, following the release of positive trial results.</p>.<p>Speaking to <em>Reuters TV</em>, Chief Executive Ugur Sahin said if all goes well, the US Food and Drug Administration could grant emergency-use approval towards the end of the first half of December or early in the second half.</p>.<p>Conditional approval in the European Union could be achieved in the second half of December, he added.</p>.<p>"It will depend on the requests that we will receive and whether all the conditions are met."</p>
<p>US and European regulators could approve Pfizer and BioNTech's experimental Covid-19 vaccine as early as mid-December, the German firm's chief executive said on Wednesday, following the release of positive trial results.</p>.<p>Speaking to <em>Reuters TV</em>, Chief Executive Ugur Sahin said if all goes well, the US Food and Drug Administration could grant emergency-use approval towards the end of the first half of December or early in the second half.</p>.<p>Conditional approval in the European Union could be achieved in the second half of December, he added.</p>.<p>"It will depend on the requests that we will receive and whether all the conditions are met."</p>